Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | NKG2D CAR T-cells & soluble NKG2D ligands

Antonio Pérez-Martínez • 5 Sep 2020
EBMT 2020
General CAR-T

Antonio Pérez-Martínez, MD, PhD, Hospital Universitario La Paz, Madrid, Spain, discusses his talk outlining NKG2D CAR T-cells and how they are not affected by soluble NKG2D ligands. The rapid expansion of the CAR-T field is commented as is the research required to move things forward. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Antonio Pérez-Martínez

1:33
Novel dual-targeting CD19/22 CAR-T therapy in relapsed ALL
Antonio Pérez-Martínez • 23 Apr 2023
1:28
Efficacy of CD45RA- T-cell infusion to treat infections in immunocompromised patients and EBV-LPDs
Antonio Pérez-Martínez • 23 Apr 2023
1:09
Outcomes following haploidentical & cord blood transplantation in pediatric patients with AML
Antonio Pérez-Martínez • 23 Apr 2023
2:02
Safety and efficacy of CD45RA+-depleted DLI in pediatric stem cell transplant recipients
Antonio Pérez-Martínez • 23 Apr 2023

Related Videos

2:00
The effectiveness of ambulatory care for patients undergoing stem cell transplantation
Amy Colada • 29 Apr 2024
2:04
The safety & efficacy of loperamide prior to stool sample results in patients undergoing SCT
Mohammad Sohomow • 29 Apr 2024
3:11
Exercise as an underutilized tool in cancer care
Rebecca Robinson • 23 Apr 2024
2:30
The impact of conflict on access to cancer therapies
Richard Sullivan • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals